Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 289480-64-4 Chemical Structure| 289480-64-4

Structure of Treprostinil sodium
CAS No.: 289480-64-4

Chemical Structure| 289480-64-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Treprostinil sodium is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.

Synonyms: UT-15 sodium; UT-15; Trevyent

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Treprostinil sodium

CAS No. :289480-64-4
Formula : C23H33NaO5
M.W : 412.49
SMILES Code : O=C([O-])COC1=CC=CC2=C1C[C@]3([H])[C@]([C@@H](CC[C@@H](O)CCCCC)[C@H](O)C3)([H])C2.[Na+]
Synonyms :
UT-15 sodium; UT-15; Trevyent
MDL No. :MFCD08141832

Safety of Treprostinil sodium

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301-H311-H331-H361
Precautionary Statements:P501-P270-P202-P201-P264-P280-P308+P313-P362+P364-P301+P310+P330-P302+P352+P312-P405
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Treprostinil sodium

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Transformed murine sinusoidal endothelial cells (TSECs) 10 µM 1-hour pretreatment followed by 48-hours exposure to busulfan To evaluate the protective effect of Treprostinil against busulfan-induced cell death. Treprostinil pretreatment significantly reduced busulfan-induced TSEC death, improving cell viability and metabolic activity. J Mol Med (Berl). 2019 Feb;97(2):201-213
IPF fibroblast-like cells 10 nM 24 hours Treprostinil reduced mitochondrial protein expression and fusion, and prevented TGF-β1-induced mitochondrial damage Int J Mol Sci. 2023 Jul 29;24(15):12148
Healthy lung fibroblasts 10 nM 24 hours Treprostinil reduced mitochondrial protein expression and fusion, and prevented TGF-β1-induced mitochondrial damage Int J Mol Sci. 2023 Jul 29;24(15):12148
Human hematopoietic stem and progenitor cells 10 µM 30 minutes To test the effect of Treprostinil alone or in combination with forskolin on cAMP accumulation, results showed that Treprostinil combined with forskolin significantly increased cAMP levels Mol Pharmacol. 2016 Jun;89(6):630-44
Murine hematopoietic stem and progenitor cells 10 µM 30 minutes To test the effect of Treprostinil alone or in combination with forskolin on cAMP accumulation, results showed that Treprostinil combined with forskolin significantly increased cAMP levels Mol Pharmacol. 2016 Jun;89(6):630-44

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Lethally irradiated mouse model Subcutaneous injection 0.15 mg/kg Every 8 hours for 10 days To test the effect of Treprostinil on survival rate after hematopoietic stem cell transplantation, results showed that Treprostinil significantly improved the survival rate of irradiated mice Mol Pharmacol. 2016 Jun;89(6):630-44
Male Sprague-Dawley rats Renal ischemia-reperfusion injury model Subcutaneous injection 100 ng/kg/min Implantation of osmotic minipumps 18-24 hours before renal IRI Treprostinil significantly reduced peak serum creatinine, BUN, ALT, and AST levels, restored hepatic levels of superoxide dismutase, glutathione, catalase, and Gclc expression to baseline, reduced lipid peroxidation, decreased hepatic Tlr9, Il-1β, Ccl2, Vcam1, and Serpine1 mRNA expression, inhibited hepatic apoptosis, enhanced hepatic ATP concentrations and mitochondrial DNA copy number, and improved mitochondrial dynamics. Biomed Pharmacother. 2021 Nov;143:112172
Sprague Dawley rats Renal ischemia-reperfusion injury model Subcutaneous injection 100 ng/kg/min Continuous administration, osmotic pumps implanted 18-24 hours before IRI To investigate the protective role of treprostinil in mitochondrial injury during renal ischemia-reperfusion injury. Results showed that treprostinil significantly reduced peak serum creatinine levels, accelerated normalization, inhibited IRI-mediated renal apoptosis, mitochondrial oxidative injury, and cytochrome c release, and preserved renal mitochondrial DNA copy number and ATP levels. Biomed Pharmacother. 2021 Sep;141:111912
Male Sprague Dawley rats Bilateral renal ischemia-reperfusion injury model Subcutaneous injection 100 ng/kg/min 18–24 hours pretreatment Treprostinil significantly improved kidney function, reduced the expression of kidney injury biomarkers, and inhibited renal inflammation and tubular epithelial apoptosis. Nephrol Dial Transplant. 2021 Jan 25;36(2):257-266
Rats Nitrofen-induced congenital diaphragmatic hernia model Subcutaneous injection 900 and 1500 ng/kg/min From gestational day (GD) 16 until term (GD 21) To evaluate the effect of Treprostinil on pulmonary hypertension associated with congenital diaphragmatic hernia. Results showed that Treprostinil reduced the medial wall thickness of pulmonary arterioles in CDH pups but increased it in normal fetuses. EBioMedicine. 2022 Jul;81:104106

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02847260 Pulmonary Arterial Hypertensio... More >>n Less << PHASE4 COMPLETED 2025-03-14 -
NCT01980979 Congenital Heart Disease WITHDRAWN 2025-12-15 UCLA Medical Center, Los Angel... More >>es, California, 90095, United States|Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, 43205, United States Less <<
NCT01416636 Non-operable Chronic Thromboem... More >>bolic Pulmonary Hypertension Less << PHASE3 COMPLETED 2025-04-21 Krankenhaus der Elisabethinen,... More >> Linz, 4020, Austria|Medical University of Vienna AKH - Division Cardiology, Vienna, Austria|II. interní klinika V?eobecná fakultní nemocnice, Prague, Czechia|Medical University Carl Gustav Carus Medizinische Klinik und Poliklinik I Medizinische Fakult?t der Technischen Universit?t Dresden, Dresden, Germany|Department of Cardiac and Vascular Diseases Centre for Rare Cardiovascular Diseases John Paul II Hospital, Krakow, 31-202, Poland|NZOZ Europejskie Centrum Zdrowia Otwock, Otwock, 05-400, Poland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.42mL

0.48mL

0.24mL

12.12mL

2.42mL

1.21mL

24.24mL

4.85mL

2.42mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories